Phenotypes Associated with This Genotype

Genotype
MGI:4834592

• Allelic Composition: Tardbp^tm1.1Pcw/Tardbp^tm1.1Pcw; Tg(CAG-cre/Esr1*)5Amc/0
• Genetic Background: involves: 129 * C57BL/6 * CBA * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

growth/size/body

decreased body weight ( J:164406 )

• after cre induction by tamoxifen, mice show decrease in body relative to controls

cellular

abnormal lipid oxidation ( J:164406 )

• increased fat oxidation after loss of Tardbp results in fat loss in adipocytes

adipose tissue

decreased total body fat amount ( J:164406 )

• inspection of animals dying after cre induction by tamoxifen shows loss of body fat in these mice

• analyses of carcasses show significant decreases in whole body fat mass, but not lean mass

abnormal brown fat cell morphology ( J:164406 )

• absence of fatty acid vacuoles in adipocytes in interscapular brown fat is detected

• adipocytes are present in brown fat, but lack of stored fat within adipocytes results in loss of fat content in animals after induction by tamoxifen

decreased mesenteric fat pad weight ( J:164406 )

• dramatic fat loss is observed

abnormal white adipose tissue morphology ( J:164406 )

abnormal white fat cell morphology ( J:164406 )

• reduction of fatty acid vacuoles in adipocytes in subcutaneous fat is detected

• adipocytes are present in white fat, but lack of stored fat within adipocytes results in loss of fat content in animals after induction by tamoxifen

homeostasis/metabolism

abnormal lipid oxidation ( J:164406 )

• increased fat oxidation after loss of Tardbp results in fat loss in adipocytes